Researchers Respond Enthusiastically to Chromatrap Technology

Porvair Filtration Group reports that considerable interest was shown in their novel Chromatrap chromatin immunoprecipitation (ChIP) assay technology recently showcased at the Epigenetics Europe congress in Munich and the Epigenomics of Common Diseases conference held at the Wellcome Trust Conference Centre in Cambridge, UK.

The Porvair Chromatrap spin column approach offers significant advantages compared to methods based on sepharose or magnetic beads, which involve many steps of separation, pipetting and re-suspension. Independent tests with Chromatrap demonstrate levels of DNA pull down up to 25 times higher than with traditional bead based procedures, excellent DNA enrichment with signal-to-noise ratios typically 2 to 3 times better than competing procedures and top performance even with samples with as few as 15,000 cells per assay.

Kevin Quinlan, Business Development Manager for the Chromatrap technology commented: "Early adopters of ChromaTrap have been delighted at the increased efficiency and precision they can routinely achieve compared to traditional bead-based ChIP technologies." He added: "Many of the pharmaceutical, healthcare and academic researchers we met at the recent congresses highlighted the need for a simpler technology to alleviate problems experienced with current ChIP assays and consequently have committed to evaluate Chromatrap technology."